Genomic Testing Helps Cancer Patients — When Results are Used

Also, liquid biopsy can ID drug-responsive tumors

CHICAGO – Genomic testing of tumor samples indicated that more than half had variants amenable to drug therapy, but only a small fraction of the patients were actually treated with appropriately targeted drugs, according to a French study reported here.

Among 1,944 patients with advanced cancer undergoing routine genomic testing, 52% were found to have these actionable alterations, but only 676 of the patients were recommended by a molecular tumor board to be treated – and just 143 patients were actually treated with some agent, said Olivier Tredan, MD, PhD, of the Centre Léon Bérard in Lyon, France.

Read Full Article Here >>